[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fireman B.V. (IFRX)

Fireman B.V. (IFRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,694
  • Shares Outstanding, K 72,293
  • Annual Sales, $ 30 K
  • Annual Income, $ -51,630 K
  • EBIT $ -46 M
  • EBITDA $ -45 M
  • 60-Month Beta 2.48
  • Price/Sales 4,030.88
  • Price/Cash Flow N/A
  • Price/Book 0.78

Options Overview Details

View History
  • Implied Volatility 53.18% (-61.11%)
  • Historical Volatility 49.89%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 831.54% on 09/11/25
  • IV Low 53.18% on 08/11/26
  • Expected Move (DTE 10) 0.0425 (2.13%)
  • Put/Call Vol Ratio 63.00
  • Today's Volume 128
  • Volume Avg (30-Day) 130
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 3,936
  • Open Int (30-Day) 4,350
  • Expected Range 1.9575 to 2.0425

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.07
  • Number of Estimates 3
  • High Estimate $-0.06
  • Low Estimate $-0.09
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +56.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6300 +23.08%
on 07/28/26
2.1000 -4.76%
on 07/13/26
-0.0500 (-2.44%)
since 07/10/26
3-Month
1.5400 +29.87%
on 06/16/26
2.9400 -31.97%
on 05/26/26
-0.5000 (-20.00%)
since 05/11/26
52-Week
0.7800 +156.74%
on 08/14/25
2.9500 -32.18%
on 05/07/26
+1.1800 (+143.01%)
since 08/11/25

Most Recent Stories

More News
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference...

IFRX : 2.0000 (+2.04%)
InflaRx (IFRX) Receives a Buy from Leerink Partners

In a report released yesterday, Joseph Schwartz from Leerink Partners reiterated a Buy rating on InflaRx, with a price target of $2.00. The company’s shares closed yesterday at $1.51.Elevate Your Investing...

IFRX : 2.0000 (+2.04%)
Infinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform Finance

The revolutionary blockchain ecosystem from Infinitum, powered by Lusis-global leader in financial systems-sets a new standard in security, resilience, and interoperability, bridging traditional and decentralized...

IFRX : 2.0000 (+2.04%)
InflaRx N.V. Receives Positive CHMP Opinion for Marketing Authorization of GOHIBIC for COVID-19 Linked Acute Respiratory Distress Syndrome Treatment

The CHMP recommends marketing authorization for InflaRx's GOHIBIC to treat COVID-19 related ARDS in certain patients.Quiver AI SummaryInflaRx N.V. announced that the Committee for Medicinal Products for...

IFRX : 2.0000 (+2.04%)
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...

IFRX : 2.0000 (+2.04%)
Stock Index Futures Move Higher Ahead of U.S. Inflation Data, Fed Minutes

June S&P 500 futures (ESM23) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.21% this morning after three major U.S. benchmark indices finished the regular session mixed as market participants...

IFRX : 2.0000 (+2.04%)
ESM23 : 4,453.35s (+0.61%)
HZON : 11.33 (+0.09%)
CFLT : 30.99 (+1.04%)
CAT : 843.37 (+0.69%)
VOLVB.S.DX : 350.400 (-1.14%)
NQM23 : 15,316.61s (+0.85%)
HTCR : 2.90 (+1.75%)
MDB : 439.16 (+5.40%)
Why InflaRx Stock Skyrocketed This Week

The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.

IFRX : 2.0000 (+2.04%)
RJF : 180.02 (+0.52%)
Why Shares of InflaRx Are Soaring Wednesday

A key EUA from the FDA for the company's COVID-19 therapy gave the stock a jolt.

IFRX : 2.0000 (+2.04%)
Stock Index Futures Move Lower as Recession Fears Weigh on Sentiment

June S&P 500 futures (ESM23) are down -0.22%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.23% this morning after three major U.S. benchmark indices finished the regular session lower as a swathe...

IFRX : 2.0000 (+2.04%)
ESM23 : 4,453.35s (+0.61%)
BE : 211.21 (+0.28%)
SGH : 20.85 (+0.43%)
JPM : 362.04 (+0.63%)
KRUS : 49.40 (+1.73%)
CI : 273.87 (-1.63%)
CAT : 843.37 (+0.69%)
JNJ : 259.80 (-0.77%)
NQM23 : 15,316.61s (+0.85%)
SW.FP : 57.400 (+1.50%)

Business Summary

InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.

See More

Key Turning Points

3rd Resistance Point 2.1400
2nd Resistance Point 2.0800
1st Resistance Point 2.0400
Last Price 2.0000
1st Support Level 1.9400
2nd Support Level 1.8800
3rd Support Level 1.8400

See More

52-Week High 2.9500
Fibonacci 61.8% 2.1200
Last Price 2.0000
Fibonacci 50% 1.8600
Fibonacci 38.2% 1.6100
52-Week Low 0.7800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.